Jennifer Hardman

Abbott (United Kingdom)

Papers

1

Total Citations

11

H-Index

1

About

Jennifer Hardman is a structural biologist whose work bridges the gap between protein dynamics and rational drug design. Her research centers on the application of mutagenesis and biophysical techniques to understand kinase regulation, with a particular focus on MAPKAP kinase 2 (MK2)—a key target in inflammatory disease. In her most-cited study, "Rational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case study" (2009, 11 citations), Hardman demonstrated how targeted mutations can stabilize flexible protein regions, enabling high-resolution crystallography and more accurate drug discovery. This work provided a methodological blueprint for overcoming conformational heterogeneity in kinases, directly impacting the design of selective inhibitors. While her citation count reflects a focused, specialized contribution, Hardman’s approach has been influential in the structural biology community, offering a practical solution to a common bottleneck in structure-based drug design. Her achievement lies not in volume of citations, but in the clarity and utility of her methodology—a testament to the value of rigorous, problem-driven research in translational science.

Research Focus

Key Achievements

1
H-Index
1
Papers
11
Total Citations
11
Avg Citations/Paper
🏆 Most Cited Paper
Rational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case study
11 citations · 2009
📈 Most Prolific Year: 2009 (1 Papers)
🤝 Key Collaborators: 17
🏛 Institutions: Abbott (United Kingdom)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago